Compare Johnson & Johnson (JNJ) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Value Index Fund ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B). The key difference: Johnson & Johnson is far larger — about 2.4× Vanguard Value Index Fund ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| JNJ | VTV | |
|---|---|---|
Market Cap | $618.09B | $262.40B |
Volume | 6,050,983 | 3,293,281 |
Sector | Health | — |
52-Week High | $278.43 | $227.51 |
52-Week Low | $186.00 | $182.86 |
Typical Hold Time | 129 Days | 142 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
VTV trades at $220.59, up 1.09% today, with a bearish technical signal overall despite bullish moving averages. The ETF offers a 2.3% dividend yield and has attracted institutional buying, as seen with QRG Capital Management increasing its stake by 14.7% in Q3 2026. Recent news highlights value stocks outperforming growth in 2026, with VTV leading among Vanguard's large-cap offerings.
The outlook for VTV is supported by the rotation into value stocks and its low 0.03% fee, but risks include underperformance versus the S&P 500 over the long term and sensitivity to interest rate changes. Investor sentiment is mixed, balancing value's resurgence against broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
